Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 2466
Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Treated with SB2 or Reference Infliximab
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2038
Radiological Changes Measured By MRI and High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Show Correlation with Michigan Hand Outcome Questionnaire (MHQ) in Rheumatoid Arthritis Patients
Measures and Measurement of Healthcare Quality Poster II- 9:00AM-11:00AM
-
Abstract Number: 2443
Randomized, Double-Blind, Single-Dose, Three-Arm Parallel Trial to Determine the Pharmacokinetics and Safety of GP2017, EU- and US-Adalimumab in Healthy Male Subjects
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2451
Rapid Onset of Response Observed with Certolizumab Pegol in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Efficacy and Safety Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2054
Rapid Tophus Resolution in Chronic Refractory Gout Patients Treated with Pegloticase
Metabolic and Crystal Arthropathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 1962
Rates of Malignancy Associated with Anti-TNF Agents and Subsequent Biologic Use after Malignancy Using U.S. SEER Registry Data
Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes- 9:00AM-11:00AM
-
Abstract Number: 2673
Real-Life Treatment Strategies for Systemic Sclerosis According to Experts
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III- 9:00AM-11:00AM
-
Abstract Number: 2454
Real-World Consistency of Response to Adalimumab over Time in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2491
Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2258
Real-World Evidence Linking Health-Related Quality of Life to Work Outcomes in Patients with Rheumatoid Arthritis
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2223
Reallocating Time Spent in Sleep, Sedentary Behavior and Physical Activity and Its Association with Pain and Depression
Pain – Basic and Clinical Aspects Poster- 9:00AM-11:00AM
-
Abstract Number: 2732
Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease
Vasculitis Poster III: Other Vasculitis Syndromes- 9:00AM-11:00AM
-
Abstract Number: 2395
Recommendations on the Management of Rheumatoid Arthritis in Patients with Cancer: A Systematic Review of Clinical Practice Guidelines and Consensus Statements
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2676
Reduction of Dlco and FVC in Patients with GERD and Systemic Sclerosis